TraceLink Announces Appointment of George Llado, former Merck and Alexion CIO, to Board of Directors
TraceLink, the leading digital network platform company enabling end-to-end product orchestration by connecting more than 290,000 entities across the Healthcare and Life Sciences industry, today announced the appointment of George Llado to the TraceLink Board of Directors.
“After spending more than a decade as a customer that depended on TraceLink’s mission-critical traceability and serialization solutions,” said Llado. “I am delighted to join TraceLink’s Board of Directors. During that time, we worked intensely together to ensure the safety and security of the medicines that patients rely on, and I look forward to playing a new, critical role in ensuring that TraceLink continues to innovate and deliver the next generation of end-to-end supply chain digitalization technologies required to increase product predictability and quality for patients with devastating diseases.”
Llado is the former Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, where he built the company’s Global Information Technology function that enables Alexion to serve patients with rare diseases. A bio-pharma industry veteran with over 35 years of business, information technology, and cyber-security experience, Llado and his team developed and implemented innovative technology and data-driven insights across Alexion’s R&D, Commercial, and Supply Chain functions.
Prior to joining Alexion, George served as Vice President and business line CIO for Merck and Co., where he led the large-scale merger integration of Merck and Schering-Plough across the IT and Shared Business Services organizations. In addition to this appointment, he serves on the Board of Charles River Laboratories and The National Center for Women & Information Technology. He also serves on the senior advisory boards of Sierra Ventures and Temple University’s Fox Business School.
“George has been an esteemed customer and partner of TraceLink from day one,” said Shabbir Dahod, President and CEO at TraceLink. “As CIO of Alexion and VP of Merck & Co., he spearheaded the implementation of TraceLink’s network for Track and Trace, Global Compliance, Contract Manufacturing Collaboration, and Supplier Performance Management. His strategic guidance helped to fuel our growth from 2 to 2,000 customers.”
In 2023, in recognition of his many contributions, George was awarded the NSBE Boston Lifetime Achievement Award. He has also been named to Forbes CIO Next list, is a Boston CIO Leadership Association’s Global CIO of the Year finalist, and is a recipient of the Information Technology Leadership Award from Temple University’s Fox Business School.
Llado will be presenting at TraceLink’s FutureLink conference May 22-24 in Boston, Massachusetts on leading digital transformation across supply chain networks, how to drive change, and find value.
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more